NCT04199741View on ClinicalTrials.gov

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 11, 2019

Primary Completion Date

June 11, 2026

Study Completion Date

June 11, 2026

Conditions
Small Cell Lung CancerSmall Cell Lung Carcinoma
Interventions
DRUG

89Zr-DFO-SC16.56

Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.

DRUG

SC16.56, Phase I, Cohort 2

7.5mg

DRUG

SC16.56, Phase I, Cohort 3

22.5mg

DRUG

SC16.56, Phase II

Dose for Phase II will be determined by results from Phase I.

Trial Locations (1)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER